Your browser doesn't support javascript.
What every intensivist should know about Tocilizumab.
Hofmaenner, Daniel Andrea; Wendel Garcia, Pedro David; Ganter, Christoph Camille; Brugger, Silvio D; Buehler, Philipp Karl; David, Sascha.
  • Hofmaenner DA; Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Wendel Garcia PD; Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Ganter CC; Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • Brugger SD; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Buehler PK; Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
  • David S; Institute of Intensive Care Medicine, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. sascha.david@usz.ch.
Crit Care ; 25(1): 262, 2021 07 27.
Article in English | MEDLINE | ID: covidwho-1477445

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Crit Care Year: 2021 Document Type: Article Affiliation country: S13054-021-03696-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Language: English Journal: Crit Care Year: 2021 Document Type: Article Affiliation country: S13054-021-03696-1